Why Immix Biopharma (IMMX) Shares Are Trading Higher Today - Immix Biopharma (NASDAQ:IMMX)

Immix Biopharma Inc IMMX announced it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 (formerly HBI0101).
In an ongoing Phase 1b study, NXC-201 showed an overall response rate (ORR) of 85% and 71% complete response/stringent complete response (CR/sCR) at the therapeutic dose from the first 20 patients with relapsed/refractory multiple myeloma.
NXC-201 also produced 100% ORR and 100% organ response rate in 4 relapsed/refractory AL Amyloidosis patients.
In addition, zero neurotoxicity of any grade and events of immune effector cell-associated neurotoxicity syndrome (ICANs) were observed.
Also see: ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug.
Immix Biopharma has formed a wholly-owned subsidiary, Nexcella Inc, to develop and potentially commercialize NXC-201.
The formation of Nexcella is expected to have a minimal impact on Immix Biopharma's financial position, as Nexcella, Inc is expected to be an independently financed company.
"Considering its short 2-day median CRS duration, occurring within a median 1-day post-dosing, we look forward to exploring outpatient administration of NXC-201," added Gabriel Morris, CFO of Immix Biopharma.
Price Action: IMMX shares are up 41.08% at $2.07 on the last check Wednesday.

Why Immix Biopharma Shares Are Surging Today?